Global Transplant Diagnostics Industry

Global Transplant Diagnostics Industry

  • April 2021 •
  • 276 pages •
  • Report ID: 5799836 •
  • Format: PDF
Abstract:
- Global Transplant Diagnostics Market to Reach $5.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Transplant Diagnostics estimated at US$3.6 Billion in the year 2020, is projected to reach a revised size of US$5.5 Billion by 2027, growing at aCAGR of 6.2% over the period 2020-2027. Molecular Assays, one of the segments analyzed in the report, is projected to record 6.9% CAGR and reach US$3.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Molecular Assays segment is readjusted to a revised 5% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $970.2 Million, While China is Forecast to Grow at 9.4% CAGR
- The Transplant Diagnostics market in the U.S. is estimated at US$970.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

- Select Competitors (Total 42 Featured) -
  • Becton, Dickinson and Company
  • Biofortuna Ltd.
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • CareDx, Inc.
  • F. Hoffmann-La Roche AG
  • GenDx
  • Hologic, Inc.
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Merck KgaA
  • Omixon
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.